A new trading day began on Friday, with Revance Therapeutics Inc (NASDAQ: RVNC) stock price up 2.12% from the previous day of trading, before settling in for the closing price of $5.18. RVNC’s price has ranged from $2.30 to $9.74 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 815.27% over the last five years. Meanwhile, its annual earnings per share averaged 50.79%. With a float of $95.08 million, this company’s outstanding shares have now reached $104.18 million.
The firm has a total of 597 workers. Let’s measure their productivity. In terms of profitability, gross margin is 69.55%, operating margin of -111.95%, and the pretax margin is -116.26%.
Revance Therapeutics Inc (RVNC) Breakdown of a Key Holders of the stock
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Revance Therapeutics Inc is 8.74%, while institutional ownership is 71.58%. The most recent insider transaction that took place on Apr 16 ’24, was worth 9,096. In this transaction Chief Commercial Officer of this company sold 2,392 shares at a rate of $3.80, taking the stock ownership to the 114,864 shares. Before that another transaction happened on Mar 18 ’24, when Company’s President sold 9,211 for $5.04, making the entire transaction worth $46,446. This insider now owns 167,550 shares in total.
Revance Therapeutics Inc (RVNC) Recent Fiscal highlights
In its latest quarterly report, released on 6/30/2024, the company reported earnings of -1.63 per share, which was $0.1 lower than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.22 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 50.79% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 11.60% during the next five years compared to 0.57% growth over the previous five years of trading.
Revance Therapeutics Inc (NASDAQ: RVNC) Trading Performance Indicators
Here are Revance Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 3.01. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.26.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.19, a number that is poised to hit -0.27 in the next quarter and is forecasted to reach -0.50 in one year’s time.
Technical Analysis of Revance Therapeutics Inc (RVNC)
Analysing the last 5-days average volume posted by the [Revance Therapeutics Inc, RVNC], we can find that recorded value of 1.25 million was lower than the volume posted last year of 2.77 million. As of the previous 9 days, the stock’s Stochastic %D was 52.60%. Additionally, its Average True Range was 0.22.
During the past 100 days, Revance Therapeutics Inc’s (RVNC) raw stochastic average was set at 68.74%, which indicates a significant increase from 66.67% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 23.34% in the past 14 days, which was lower than the 124.78% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $5.93, while its 200-day Moving Average is $4.75. Now, the first resistance to watch is $5.45. This is followed by the second major resistance level at $5.60. The third major resistance level sits at $5.78. If the price goes on to break the first support level at $5.12, it is likely to go to the next support level at $4.94. Now, if the price goes above the second support level, the third support stands at $4.79.
Revance Therapeutics Inc (NASDAQ: RVNC) Key Stats
With a market capitalization of 551.11 million, the company has a total of 104,449K Shares Outstanding. Currently, annual sales are 234,040 K while annual income is -323,990 K. The company’s previous quarter sales were 65,390 K while its latest quarter income was -37,470 K.
